...
首页> 外文期刊>Biochimica et biophysica acta. Biomembranes >Heat-activated liposome targeting to streptavidin-coated surfaces
【24h】

Heat-activated liposome targeting to streptavidin-coated surfaces

机译:热激活脂质体靶向链霉亲和素包被的表面

获取原文
获取原文并翻译 | 示例

摘要

There is a great need of improved anticancer drugs and corresponding drug carriers. In particular, liposomal drug carriers with heat-activated release and targeting functions are being developed for combined hyperthermia and chemotherapy treatments of tumors. The aim of this study is to demonstrate the heat-activation of liposome targeting to biotinylated surfaces, in model experiments where streptavidin is used as a pretargeting protein. The design of the heat-activated liposomes is based on liposomes assembled in an asymmetric structure and with a defined phase transition temperature. Asymmetry between the inside and the outside of the liposome membrane was generated through the enzymatic action of phospholipase D, where lipid head groups in the outer membrane leaflet, i.e. exposed to the enzyme, were hydrolyzed. The enzymatically treated and purified liposomes did not bind to streptavidin-modified surfaces. When activation heat was applied, starting from 22 degrees C, binding of the liposomes occurred once the temperature approached 33 +/- 0.5 degrees C. Moreover, it was observed that the asymmetric structure remained stable for at least 2 weeks. These results show the potential of asymmetric liposomes for the targeted binding to cell membranes in response to (external) temperature stimulus. By using pretargeting proteins, this approach can be further developed for personalized medicine, where tumor-specific antibodies can be selected for the conjugation of pretargeting agents. (C) 2015 Published by Elsevier B.V.
机译:迫切需要改进的抗癌药物和相应的药物载体。特别地,具有热激活释放和靶向功能的脂质体药物载体正在被开发用于肿瘤的热疗和化学疗法的组合。这项研究的目的是在将链霉亲和素用作预靶向蛋白的模型实验中,证明脂质体靶向生物素化表面的热激活。热活化脂质体的设计基于组装成不对称结构且具有确定的相变温度的脂质体。脂质体膜的内部和外部之间的不对称是通过磷脂酶D的酶促作用产生的,其中外膜小叶中的脂质头基团(即暴露于该酶的酶)被水解。经酶处理和纯化的脂质体不结合链霉亲和素修饰的表面。当从22℃开始施加活化热时,一旦温度达到33 +/- 0.5℃,脂质体就发生结合。此外,观察到不对称结构保持稳定至少2周。这些结果表明响应于(外部)温度刺激,不对称脂质体具有靶向结合细胞膜的潜力。通过使用预靶向蛋白,可以进一步开发该方法用于个性化药物,其中可以选择肿瘤特异性抗体来结合预靶向剂。 (C)2015由Elsevier B.V.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号